Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia 5Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Blast Crisis 4Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Piebaldism 1Philadelphia Chromosome 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Malignant Hepatobiliary Neoplasm 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hematologic Diseases 1Glioblastoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Medullary 1Carcinoma 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Bone Marrow Diseases 1

Interventions

ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Malignant Hepatobiliary Neoplasm × ponatinib × Clear all
NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Mayo Clinic

Phase 2 Completed
12 enrolled 11 charts
Gastrointestinal

Malignant Hepatobiliary Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡